Personalized medicine with drugs targeting the underlying protein defect in cystic fibrosis: is monitoring of treatment response necessary?

Cystic fibrosis (CF) is caused by two mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. In the last years, drugs targeting the underlying protein defect like lumacaftor/ivacaftor (LUM/IVA) or tezacaftor/ivacaftor (TEZ/IVA) and more recently elexacaftor/tezacaftor/ivac...

Descripción completa

Detalles Bibliográficos
Autores principales: Niedermayr, Katharina, Gasser, Verena, Rueckes-Nilges, Claudia, Appelt, Dorothea, Eder, Johannes, Fuchs, Teresa, Naehrlich, Lutz, Ellemunter, Helmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358561/
https://www.ncbi.nlm.nih.gov/pubmed/35959505
http://dx.doi.org/10.1177/20406223221108627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358561/
https://www.ncbi.nlm.nih.gov/pubmed/35959505
http://dx.doi.org/10.1177/20406223221108627

Ejemplares similares